Syndrome News and Research

RSS

Study provides a reliable early prognostic biomarker for COVID-19 severity

In a retrospective, multi-centre cohort study conducted by researchers from Nanjing University, Huazhong University of Science and Technology, Jinling Hospital and the Second Hospital of Nanjing, a microRNA-like small RNA encoded by SARS-CoV-2 was identified in the serum of COVID-19 patients, which can be developed as a non-invasive biomarker for stratification of severe patients from mild/moderate ones and for identification of high-risk individuals before clinical manifestation of severe symptoms.

6 Jul 2021

Angiotensin II type 1 receptor-targeting autoantibodies may increase COVID-19 severity

A team of US-based scientists recently demonstrated that pro-thrombotic autoantibodies that target angiotensin II type 1 receptor (AT1R) may be associated with endothelial complications observed in coronavirus disease 2019 (COVID-19), a novel disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

6 Jul 2021

Serum testosterone status recovery an accurate predictor of survival in male COVID-19 patients

In a study available on the medRxiv* the preprint server, researchers from Spain showed that testosterone trajectories are very accurate individual predictors of survival in male patients with COVID-19. To better understand the relationship between testosterone levels and disease severity, they studied a group of male and female COVID-19 patients assessing their serum and blood biomarkers in association with outcome of disease.

6 Jul 2021

Study examines evolution and avidity of anti-SARS-CoV-2 IgG antibodies after mRNA vaccination

New research released on the medRxiv* preprint server has measured antibody responses in 71 mRNA vaccinated adults (54 vaccinated with Pfizer and 17 vaccinated with Moderna).

6 Jul 2021

Study explores the effects of SARS-CoV-2 (and other betacoronaviruses) on cellular mRNA processing

A new study has been released on the bioRxiv* preprint server, which deals with a comprehensive survey on alternative splicing concerning SARS-CoV-2 infection. This study has also included two other betacoronavirurses (SARS-CoV and MERS), a control set of unrelated viruses, and a bacterium, namely, Streptococcus pneumonia. The study findings suggest that several cellular parameters are affected owing to a betacoronavirus infection, which in turn affects some genes and invariably various biological functions.

6 Jul 2021

COVID-19 recovered vaccinated individuals more protected from Delta variant

The B.1.617 lineage of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first detected in October 2020, has led to new outbreaks of the infection and new waves of the pandemic. This infectious lineage has resulted in the generation of sub-lineages such as B.1.617.1 (Kappa), B.1.617.2 (Delta) and B.1.617.3.

6 Jul 2021

CRISPRa identifies potassium channels as neuronal entry factors and druggable targets for SARS-CoV-2

New research led by Le Cong of Stanford University School of Medicine in California indicates that the KCNA6 potassium channel may help with viral entry and promote infection. In addition, KCNA6 is highly expressed in OLIG2+ neuronal cells, which has been shown to be suspectable to SARS-CoV-2 in the olfactory neuroepithelium. This area appears to contribute to loss of smell commonly observed during infection.

6 Jul 2021

Study explores how human ACE2 variants can modify SARS-CoV-2 binding

A recent tour-de-force study by researchers from the United Kingdom reveals variants of the human angiotensin-converting enzyme 2 (ACE2) that can improve or decrease binding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – including two variants with distinct population distributions showing an enhanced affinity for viral spike glycoprotein.

5 Jul 2021

Antibiotic clofoctol shows potential against SARS-CoV-2

In a recent study, a group of French researchers aimed to reduce the regulatory preclinical development steps that potential candidates are normally subjected to.

5 Jul 2021

COVID-19's long-term effects on chemosensory functions

A group of Canadian researchers has recently conducted a comprehensive study investigating the long-term effects of COVID-19.

5 Jul 2021

Study says mRNA COVID vaccines are effective against Lambda variant

Researchers in the United States have conducted a study suggesting that the coronavirus disease 2019 (COVID-19) vaccines that are currently being rolled out in many countries should be effective against the C.37 lineage (lambda variant) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

5 Jul 2021

Lack of symptoms following COVID-19 mRNA vaccination doesn't mean vaccine not working

A study conducted by researchers from Maryland in the United States has found no correlation between the symptoms that develop following vaccination against coronavirus disease 2019 (COVID-19) and the antibody responses that are generated against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

5 Jul 2021

Scientists identify breakthrough cases of SARS-CoV-2’s delta variant in fully vaccinated individuals

In a recent study conducted at the Baylor College of Medicine, Houston, USA, scientists have identified six vaccine breakthrough cases caused by the delta variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

5 Jul 2021

New study attempts to characterize long-COVID in all its complexity

In a new meta-study, a large subset of reports on post-viral complications in individuals following a SARS-CoV-2 infection have been organized and categorized, mapping 287 unique clinical findings related to long-COVID.

5 Jul 2021

Thiol-based mucolytics show potent allosteric inhibition of SARS-CoV-2-ACE2 binding via disulfide reduction

A compelling report, recently released on the bioRxiv* preprint server, describes unexpectedly powerful inhibition of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by thiol-based mucolytic compounds P2119 and P2165, by preventing the virus spike from binding to its host cell receptor, the angiotensin-converting enzyme 2 (ACE2).

5 Jul 2021

Dimeric IgA antibodies help identify recent SARS-CoV-2 infection

A fascinating new study, released as a preprint on the medRxiv* server, adds a highly appealing tool to the armory of detection techniques for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Its validation could allow the early and accurate detection of recent or active infection, which is valuable in tracing contacts and preventing forward transmission of the virus.

5 Jul 2021

Varenicline blocks SARS-CoV-2 infection in cells and animal models

A new paper released on the bioRxiv* preprint server suggests that the nicotinic acetylcholine receptor (nACHR) agonist, varenicline tartrate, has antiviral activity against the virus.

5 Jul 2021

Scientists identify natural SARS-CoV-2 super immunity against 23 variants

The antibodies are capable of neutralizing a wide range of SARS-CoV-2 variants even at sub-nanomolar concentrations. In addition, the combinations of these antibodies reduce the risk of generating escape mutants in vitro. The study is published in the journal Science.

5 Jul 2021

Novavax COVID-19 vaccine demonstrates ~90% efficacy against SARS-CoV-2

The findings reveal that the two-dose regimen of the vaccine is almost 90% effective against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Moreover, the vaccine shows high efficacy against the B.1.1.7 variant (Alpha) of SARS-CoV-2.

5 Jul 2021

Rapid quantification of SARS-CoV-2 Spike-specific T cells by direct peptide stimulation of whole peripheral blood

To understand both the correlates of protection induced by vaccinations and the necessary immune responses to manage the COVID-19, researchers from Singapore used an alternative method to closely evaluate the kinetics and magnitude of specific T cell responses to SARS-CoV-2 infection. Their work was posted to the bioRxiv* preprint server while awaiting peer review.

5 Jul 2021

Syndrome News and Research

Study provides a reliable early prognostic biomarker for COVID-19 severity

Angiotensin II type 1 receptor-targeting autoantibodies may increase COVID-19 severity

Serum testosterone status recovery an accurate predictor of survival in male COVID-19 patients

Study examines evolution and avidity of anti-SARS-CoV-2 IgG antibodies after mRNA vaccination

Study explores the effects of SARS-CoV-2 (and other betacoronaviruses) on cellular mRNA processing

COVID-19 recovered vaccinated individuals more protected from Delta variant

CRISPRa identifies potassium channels as neuronal entry factors and druggable targets for SARS-CoV-2

Study explores how human ACE2 variants can modify SARS-CoV-2 binding

Antibiotic clofoctol shows potential against SARS-CoV-2

COVID-19's long-term effects on chemosensory functions

Study says mRNA COVID vaccines are effective against Lambda variant

Lack of symptoms following COVID-19 mRNA vaccination doesn't mean vaccine not working

Scientists identify breakthrough cases of SARS-CoV-2’s delta variant in fully vaccinated individuals

New study attempts to characterize long-COVID in all its complexity

Thiol-based mucolytics show potent allosteric inhibition of SARS-CoV-2-ACE2 binding via disulfide reduction

Dimeric IgA antibodies help identify recent SARS-CoV-2 infection

Varenicline blocks SARS-CoV-2 infection in cells and animal models

Scientists identify natural SARS-CoV-2 super immunity against 23 variants

Novavax COVID-19 vaccine demonstrates ~90% efficacy against SARS-CoV-2

Rapid quantification of SARS-CoV-2 Spike-specific T cells by direct peptide stimulation of whole peripheral blood

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News